91 related articles for article (PubMed ID: 2460019)
21. Expression of vimentin and cytokeratin types of intermediate filament proteins in developing and adult human kidneys.
Holthöfer H; Miettinen A; Lehto VP; Lehtonen E; Virtanen I
Lab Invest; 1984 May; 50(5):552-9. PubMed ID: 6201675
[TBL] [Abstract][Full Text] [Related]
22. Cytokeratin expression during neoplastic progression of human transitional cell carcinomas as detected by a monoclonal and a polyclonal antibody.
Ramaekers F; Huysmans A; Moesker O; Schaart G; Herman C; Vooijs P
Lab Invest; 1985 Jan; 52(1):31-8. PubMed ID: 2578201
[TBL] [Abstract][Full Text] [Related]
23. Pinkus tumor may originate from intraepidermal eccrine ducts and proliferate in the dermis.
Kurokawa I; Yokoyama T; Nishimura K; Hakamada A; Isoda K; Yamanaka K; Tsubura A; Mizutani H
Oncol Rep; 2007 Jan; 17(1):49-54. PubMed ID: 17143477
[TBL] [Abstract][Full Text] [Related]
24. Evolution of cytokeratin expression in developing human tooth germ.
Pelissier A; Ouhayoun JP; Sawaf MH; Forest N
J Biol Buccale; 1990 Jun; 18(2):99-108. PubMed ID: 1698767
[TBL] [Abstract][Full Text] [Related]
25. [Specific characteristics of skin basal cell carcinoma invasion].
Doĭkova NG; Chernyĭ AP; Chipysheva TA; Gel'shteĭn VI
Arkh Patol; 2000; 62(3):29-33. PubMed ID: 10897434
[TBL] [Abstract][Full Text] [Related]
26. Cross-reactivity of murine anti-human high molecular weight-melanoma associated antigen monoclonal antibodies with guinea pig melanoma cells.
Liao SK; Smith JW; Kwong PC; Natali PG; Kusama M; Hamby CV; Ferrone S
Cancer Res; 1987 Sep; 47(18):4835-41. PubMed ID: 3476198
[TBL] [Abstract][Full Text] [Related]
27. Expression of keratin mRNAs and proteins in normal salivary epithelia and pleomorphic adenomas.
Su L; Morgan PR; Harrison DL; Waseem A; Lane EB
J Pathol; 1993 Nov; 171(3):173-81. PubMed ID: 7506306
[TBL] [Abstract][Full Text] [Related]
28. Elastic fiber staining and cytokeratin 15 expression pattern in trichoepithelioma and basal cell carcinoma.
Choi CW; Park HS; Kim YK; Lee SH; Cho KH
J Dermatol; 2008 Aug; 35(8):499-502. PubMed ID: 18789069
[TBL] [Abstract][Full Text] [Related]
29. Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
Stoebner PE; Le Gallic L; Berthe ML; Boulle N; Lallemant B; Marque M; Gaspard C; Delfour C; Lavabre-Bertrand T; Martinez J; Meunier L
Exp Dermatol; 2008 Nov; 17(11):908-15. PubMed ID: 18341568
[TBL] [Abstract][Full Text] [Related]
30. A cytokeratin profile of canine epithelial skin tumours.
Walter J
J Comp Pathol; 2000 May; 122(4):278-87. PubMed ID: 10805981
[TBL] [Abstract][Full Text] [Related]
31. Cellular differentiation of basal cell carcinoma studied with fluorescent lectins and cytokeratin antibodies.
Kariniemi AL; Holthöfer H; Vartio T; Virtanen I
J Cutan Pathol; 1984 Dec; 11(6):541-8. PubMed ID: 6084019
[TBL] [Abstract][Full Text] [Related]
32. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
33. Innovative 19-minute rapid cytokeratin immunostaining of nonmelanoma skin cancer in Mohs micrographic surgery.
Cherpelis BS; Turner L; Ladd S; Glass LF; Fenske NA
Dermatol Surg; 2009 Jul; 35(7):1050-6. PubMed ID: 19469800
[TBL] [Abstract][Full Text] [Related]
34. A keratin antibody recognizing a heterotypic complex: epitope mapping to complementary locations on both components of the complex.
Waseem A; Lane EB; Harrison D; Waseem N
Exp Cell Res; 1996 Mar; 223(2):203-14. PubMed ID: 8601396
[TBL] [Abstract][Full Text] [Related]
35. Profiles of keratin proteins in basal and squamous cell carcinomas of the skin. An immunohistochemical study.
Thomas P; Said JW; Nash G; Banks-Schlegel S
Lab Invest; 1984 Jan; 50(1):36-41. PubMed ID: 6198559
[TBL] [Abstract][Full Text] [Related]
36. [Proliferating patterns of basal cell carcinoma--immunohistological study by means of anti-BrdU monoclonal antibody].
Yoshimura K; Egawa K; Ono T
Nihon Hifuka Gakkai Zasshi; 1990 Apr; 100(5):575-80. PubMed ID: 2395219
[TBL] [Abstract][Full Text] [Related]
37. Anti-cytokeratin CAM 5.2 does not act as a surrogate of the cytokeratin 8/18 monoclonal antibody. Comment on: "Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma", in J Cutan Pathol 2009; 36: 543.
Chen JT; Hsu JD; Yao CC; Han LW; Han CP
J Cutan Pathol; 2010 Oct; 37(10):1123-4. PubMed ID: 20175827
[No Abstract] [Full Text] [Related]
38. [An immunohistochemical study on basal cell epithelioma using anti-keratin monoclonal antibodies].
Shimizu N
Nihon Hifuka Gakkai Zasshi; 1987 May; 97(6):691-7. PubMed ID: 2442439
[No Abstract] [Full Text] [Related]
39. Anti-cytokeratin CAM 5.2 is specific for K8 and to a lesser extent for the closely related K7, but shows no reactivity with K18 or K19: comment on: "keratin expression in endocrine organs and their neoplasms" Endocr Pathol. 2009 Spring; 20(1):1-10.
Chen PJ; Hsu JD; Han CP
Endocr Pathol; 2010 Mar; 21(1):69-70; author reply 71. PubMed ID: 20174893
[No Abstract] [Full Text] [Related]
40. The distribution of cytokeratin antigens in the kidney and in renal tumours.
Fleming S; Symes CE
Histopathology; 1987 Feb; 11(2):157-70. PubMed ID: 2437002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
